

Amarantus Bioscience Holdings, Inc.  
Form 8-K  
November 18, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 18, 2014**

**AMARANTUS BIOSCIENCE HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

**333-148922**

**26-0690857**

(State or other jurisdiction of incorporation or organization) (Commission File Number)

IRS Employer

Identification No.)

**655 Montgomery Street**

**Suite 900**

**94111**

**San Francisco, CA**

Edgar Filing: Amarantus Bioscience Holdings, Inc. - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

**(408) 737-2734**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Other Events

Amarantus Bioscience Holdings, Inc. (the “Company”) intends to use the corporate presentation attached to this Current Report on Form 8-K as Exhibit 99.1 (the “Slides”), in whole or in part, and possibly with modifications, in connection with its presentation to stockholders and potential investors.. The Slides are attached as Exhibit 99.1 to this report on Form 8-K and are incorporated herein by reference.

### Item 8.01

The information contained in the Slides is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

### Item 9.01 Financial Statements and Exhibits.

*(d) Exhibits*

Exhibit No.	Description
----------------	-------------

99.1	Corporate presentation dated November 18, 2014
------	--

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**AMARANTUS BIOSCIENCE  
HOLDINGS, INC.**

Date:

November 18, 2014 By: */s/ Gerald E. Commissiong*

Name: Gerald E. Commissiong  
Title: Chief Executive Officer